This trial is concluded. This means the trial has been completed. When the results of the trial have been made public, they will be summarised in the 'outcomes' section of this page. You cannot enrol in this trial.
About this trial
This study is looking at how safe and effective it is to treat HIV with a combination of just two drugs: raltegravir and atazanavir. The study will compare once-daily with twice-daily doses of the drugs.
Background information
Current HIV treatment guidelines recommend combination regimens comprising a minimum of three agents from at least two drug classesA group of anti-HIV drugs with the same target of action. Anti-HIV drug classes include nucleoside analogue reverse transcriptase inhibitors, protease inhibitors and non-nucleoside analogue reverse transcriptase inhibitors, as well as several others. Combining drugs from three or more classes is the basis of Highly Active Antiretroviral Therapy (HAART).. There are problems with the current recommendations because although treatments are effective, their success is often limited by tolerability, adverse effects and the need to take many pills.
AntiretroviralA medication or other substance which is active against retroviruses such as HIV. adherence remains vital and regimens should be simplified wherever possible to facilitate maximal adherence.
The recent availability of raltegravir from the new class of integrase inhibitors provides an opportunity to explore moves away from current regimen components.
Evidence to support the use of novel regimens must be generated through adequately powered randomisedA method based on chance by which study participants are assigned to a treatment group. Randomization minimizes the differences among groups by equally distributing people with particular characteristics among all the trial arms. The researchers do not know which treatment is better. From what is known at the time, any one of the treatments chosen could be of benefit to the participant clinical trials. However, before such trials can be undertaken, preliminary data to define the pharmacokinetics, safety and tolerability of these regimens are needed to minimise unnecessary risk for participants. This eight week study will investigate the short-term safety and efficacy(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of two dosing strategies (once and twice daily) of raltegravir plus atazanavir in treatment experienced people.
NAPWA commentary
An optional component of this study is volunteering to donate a sample of your semen and/or spinal fluid. The purpose of this is so they can compare the viral loadA measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. and quantity of drug in your blood sample with that in samples of other body fluids to see if there is any difference. While this is an important component of this study it is definitely not compulsory.
| Official title: | A Randomised, Open-Label, Cross-Over Study to Examine the Pharmacokinetics and Short-Term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-Infected Patients |
|---|
| What is this trial studying? | Treatment strategy – atazanavir, raltegravir |
|---|
| Start date: | to be determined This may be the proposed or expected start date for trials which have not yet started. |
|---|
| How many participants will this trial enrol? | 24 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
|---|
| How long is this trial planned to go for? | Participants in this trial will be asked to follow the treatment strategy for 8 weeks. |
|---|
| Links to further information: | |
|---|
| Can I access this treatment other than by enrolling in this trial? | Both raltegravir and atazanavir are available through the PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs..
|
|---|
| Tags: | atazanavir, first-line therapy, raltegravir |
|---|
Who can enrol in this trial?
You may be eligible to participate in this trial if you meet the following criteria:
- At least 18 years old
- Currently taking HIV treatments
- currently receiving atazanavir as part of combination therapy for at least 6 months
This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.
This site complies with the HONcode standard for trustworthy health information: verify here. 
